Table 3.
Symptom durationa in patients with COVID-19 in treatment group or control group.
| Symptom | HCQ group | Control group | p value |
|---|---|---|---|
| Headache | 8 (1–41) | 9 (2–41) | 0.413 |
| Smell and taste disorders | 16 (4–40) | 28 (1–39) | 0.078 |
| Muscle pain | 9 (1–54) | 8 (1–41) | 0.483 |
| Fatigue | 12 (1–44) | 16 (2–42) | 0.415 |
| Fever | 3 (1–15) | 3 (1–44) | 0.550 |
| Nasal congestion | 12 (1–41) | 12 (1–39) | 0.871 |
| Cough | 12 (1–44) | 19 (2–41) | 0.084 |
| Sore throat | 5 (1–41) | 14 (2–45) | 0.012 |
| Anorexia | 9 (3–36) | 13 (3–33) | 0.775 |
| Shortness of breath | 6 (1–33) | 10 (1–41) | 0.373 |
| Diarrhea | 4 (1–32) | 5 (1–36) | 0.579 |
| Chest pain | 10 (4–33) | 13 (3–41) | 0.838 |
| Sputum production | 14 (1–41) | 30 (5–41) | 0.271 |
| Eye discomfort | 8 (2–33) | 33 (7–44) | 0.052 |
Data are median days (minimum–maximum).
a
Duration of symptoms was calculated until symptom finalization, or study finalization for those who persisted.